Telemonitoring Spirometry and Oximetry in CTD-ILD: Prospective Cohort Study

Overview

This prospective observational cohort study evaluated the acceptability, usability, and adherence to home spirometry and oximetry monitoring in patients with interstitial lung disease associated with connective tissue disorders (CTD-ILD) compared to idiopathic pulmonary fibrosis (IPF). The study demonstrated feasibility of remote monitoring using handheld devices linked to smartphone applications, highlighting challenges unique to CTD patients and the potential for early detection of disease progression.

Background

Connective tissue diseases (CTDs) are multisystem autoimmune disorders frequently complicated by interstitial lung disease (ILD), which contributes significantly to morbidity and mortality. Pulmonary function tests, including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO), are essential for monitoring ILD progression. Home spirometry and pulse oximetry offer opportunities for remote monitoring, potentially enabling early detection of exacerbations and timely intervention. However, CTD patients may face unique challenges using handheld devices due to factors such as impaired hand function and Raynaud's phenomenon.

Data Highlights

Participants with CTD-ILD and IPF were provided with handheld spirometers and pulse oximeters connected via Bluetooth to smartphone apps for weekly home monitoring. Adherence was defined as >70% weekly monitoring over the study period. Patient-reported outcome measures and a 24-question survey assessed usability and acceptability. Devices included Medical International Research Spirobank Smart spirometers and Nonin pulse oximeters, with ear-clip oximeters provided for those with Raynaud’s phenomenon. The study excluded participants without smartphone/internet access or with life expectancy under 12 months.

Key Findings

• Home spirometry and oximetry monitoring in CTD-ILD patients is feasible and acceptable, with adherence comparable to IPF patients.
• CTD patients face unique challenges such as microstomia affecting spirometer use and Raynaud’s phenomenon impacting oximetry accuracy.
• Bluetooth-enabled handheld devices linked to smartphone apps allow real-time data transmission accessible to patients and healthcare providers.
• Patient-reported outcome measures and surveys indicate overall ease of use and perceived benefit of home monitoring.
• Early detection of pulmonary function decline via telemonitoring may facilitate prompt clinical interventions and potentially reduce hospitalizations.

Clinical Implications

Remote home monitoring using handheld spirometers and pulse oximeters is a practical approach for managing patients with CTD-ILD, enabling frequent assessment of lung function and oxygenation outside clinical settings. Clinicians should consider patient-specific factors such as hand function and peripheral circulation when implementing telemonitoring. This strategy may improve early identification of disease progression and guide timely therapeutic adjustments.

Conclusion

Telemonitoring of spirometry and oximetry is a feasible and acceptable method for monitoring patients with CTD-ILD, offering a valuable tool to complement traditional clinical assessments. Addressing device usability challenges specific to CTD patients can optimize adherence and data quality, ultimately enhancing disease management.

References

1. Nakshbandi et al. -- Adapted 24-question survey for home monitoring
2. American Thoracic Society et al. -- IPF diagnostic guidelines
3. Beaumont Hospital REC 20/24 -- Ethics approval for study
4. ClinicalTrials.gov NCT06702228 -- Study registration